Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
about
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individualsCalcium channel blockers versus other classes of drugs for hypertensionPharmacotherapy for hypertension in the elderlyBlood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementiaBlood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertensionRisk factor thresholds: their existence under scrutinyFollow-up of a major linkage peak on chromosome 1 reveals suggestive QTLs associated with essential hypertension: GenNet studyDebate: The slippery slope of surrogate outcomesThe Blood Pressure "Uncertainty Range" - a pragmatic approach to overcome current diagnostic uncertainties (II)Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2)A cost-minimization analysis of diuretic-based antihypertensive therapy reducing cardiovascular events in older adults with isolated systolic hypertensionDiuretics: again the first step in the treatment of most patients with hypertensionEffect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysesUnderstanding and treating hypertension in diabetic populationsVascular aspects of cognitive impairment and dementiaWhat is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendationsThe Hypertension in the Very Elderly Trial - latest dataBlood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analysesAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Managing hypertension in the elderly: a common chronic disease with increasing ageIs blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) andThe treatment of hypertension in people with dementia: a systematic review of observational studiesA Randomized Trial of Intensive versus Standard Blood-Pressure ControlSystolic BP and Mortality in Older Adults with CKD.PURLs: "Go low" or say "No" to aggressive systolic BP goals?Primary prevention: do the very elderly require a different approach?Primary prevention of coronary heart disease in the elderlyQueen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996-2004Treatment of the elderly post-myocardial infarction patientPharmacological interventions for peripheral artery diseaseThe effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trialsNifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2Randomised double-blind comparison of placebo and active drugs for effects on risks associated with blood pressure variability in the Systolic Hypertension in Europe trialTreatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets.Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of HypertensionCost-effectiveness of a hypertension management programme in an elderly population: a Markov model.Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
P2860
Q24186039-DFC70181-5AA0-4ACD-99FF-2B0866F7F46FQ24236584-C42B826C-370C-4691-AD03-26D7B4DDAB7BQ24240189-064CC4AD-CD73-4598-B5B1-4FA9ADE8C6F2Q24240206-A0622CC2-0E39-4D19-B2AC-63709CA4B927Q24240505-0AFA6356-9893-4A6B-A143-5C02C8446F2FQ24527206-A6BC723B-47DA-4655-8274-0E96B51012D5Q24650582-9731563F-731C-4594-BDB4-2FEAC2745538Q24792578-FB50EA91-2F02-4B32-B3C7-5F835840959AQ24793325-10AEFB77-4FA6-46FD-BAA5-AAD3CCC3AF63Q24795084-B99743B3-E897-49B9-ADD4-CF59D02E0871Q24799416-75223D8C-85AD-4CC4-8CAF-587F64C615FAQ24799879-B16D5833-094C-471D-9793-6BBD7B0E47D4Q24806951-616D2013-145A-45C9-BD5C-89192E106DB6Q26766025-BE533304-7492-4F4E-823B-630DC17BF040Q26778662-916CD4E8-4800-4FFE-AF77-5DDDF66450B0Q26820823-706C2B15-FF97-4125-A814-05E5C54DB097Q26864349-21551543-3007-4B05-83F4-23B324111CCAQ26865806-60EFB811-0C6B-4F0F-BAAE-597C7C2F9327Q26996563-DDDF69D8-520E-4E9B-A2A1-EEC142BC6A08Q27002538-FACEF1B6-22FC-43A5-AE71-FF9E0C3A5083Q27011805-F020FA2A-7FA7-4E9A-84EF-FB0F84F4DBB2Q27025943-A16D3A64-D5F4-4073-8830-8E52A9D0CAFBQ27026345-888A0762-A9A4-4EB0-8BD0-718EB72AB993Q27231406-90F9B706-B512-40CB-B3A5-89FD880DF66DQ27335475-A145A9CA-FCB6-4E78-B013-028CF7D812ECQ28078922-63A814AE-524A-44EC-AC6E-EE585A5C2102Q28080456-89E24310-0E30-4C64-A6B5-0E287F7D7178Q28165739-1D17C095-3727-4C83-B29B-EE4D26F8E165Q28180976-AA6D9DFB-3967-4082-939D-3EA480951979Q28191018-85BC7BD2-F70D-46FD-9C39-6DE84C29875DQ28218976-A125BB9A-02E3-4F68-8258-479B2308D5BDQ28487721-CB2B4C1D-B771-47CA-A489-F1FEE1341CC2Q28578027-0E12B75A-E503-47D8-AE54-0E58DE351BB2Q28654977-9B48A9F3-4E25-40BF-B0AA-CA34198A38EEQ30245219-625C1A04-AF9E-4BCB-B3DA-60E95A191249Q30499043-D457742F-216B-4735-9992-29F116FA8A83Q30499045-5495A6EE-586B-4715-A371-D06A484FC843Q30499940-F7DA385F-F48D-4F03-A356-82D57F9989C8Q30514101-B565D953-C1B2-4053-888A-8758BFD68EB0Q30574638-BDAAB7C3-F5B8-447E-85F7-26512678BDF3
P2860
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Randomised double-blind compar ...... Syst-Eur) Trial Investigators.
@en
Randomised double-blind compar ...... ystolic Hypertension in Europe
@nl
type
label
Randomised double-blind compar ...... Syst-Eur) Trial Investigators.
@en
Randomised double-blind compar ...... ystolic Hypertension in Europe
@nl
prefLabel
Randomised double-blind compar ...... Syst-Eur) Trial Investigators.
@en
Randomised double-blind compar ...... ystolic Hypertension in Europe
@nl
P2093
P50
P921
P1433
P1476
Randomised double-blind compar ...... Syst-Eur) Trial Investigators.
@en
P2093
A E Fletcher
A Zanchetti
C J Bulpitt
C T Dollery
E T O'Brien
G G Arabidze
G Leonetti
P304
P356
10.1016/S0140-6736(97)05381-6
P407
P577
1997-09-01T00:00:00Z